Federal regulators have approved a new instrument made by Dune Medical Devices Inc. that enables breast cancer surgeons to determine immediately whether they have removed all of the cancer tissue during lumpectomy procedures, the company is set to disclose Wednesday.

Dune Medical, based in Caesarea, Israel, plans to move its US office from Framingham to Boston’s Innovation District next week as it builds a sales force to market the device, called the MarginProbe system, to breast cancer surgeons across the nation.